期刊文献+

噻托溴铵与沙美特罗替卡松对慢性阻塞性肺疾病稳定期疗效比较 被引量:8

Comparision of Therapeutic Effects between Tiotropium Bromide and Salmeterol/Fluticasone Propionate on Stationary Phases of Chronic Obstructive Pulmonary Disease
下载PDF
导出
摘要 目的评价噻托溴铵与沙美特罗替卡松对慢性阻塞性肺疾病(COPD)稳定期疗效。方法采用随机平行对照研究,将筛选合格的稳定期中重度COPD患者68例随机分为A、B两组,各34例。分别给予吸入噻托溴铵和沙美特罗替卡松粉剂。比较二者在治疗前、治疗后2及4周肺功能中一秒钟用力呼气量(FEV1)和一秒钟用力呼气量和用力肺活量比值(FEV1/FVC)的改变。结果68例受试者最终完成试验55例,其中A组25例,B组30例。治疗后二组肺功能均有明显改善;St George’呼吸问卷得分值降低,生活质量上升。B组患者依从性较好,稳定期内急性发作次数明显减少。结论噻托溴铵和沙美特罗替卡松粉剂对中重度慢性阻塞性肺疾病患者的肺功能及生活质量改善疗效均较好。沙美特罗替卡松粉剂患者依从性较好。 Objective To compare therapeutic effects between tiotropium bromide and salmeterol/ fluticasone propionate on stationary phases of chronic obstructive pulmonary disease (COPD). Methods A randomized and parallel comparison was conducted in 68 eligible patients with stable moderate to severe COPD, whom were randomized into two groups, inhaling tiotropium bromide as group A and inhaling salmeteroL/ fluticasone propionate as group B. To compare the value of FEV1 and FEV1/FVC before treatment and 2- week , 4-week after treatment. Results 55 patients completed clinical trial,including 25 cases inhaling tiotropium bromide and 30 cases inhaling salmeterol/fluticasone propionate. The lung function was significantly improved in two groups before and after treatment. The score in St George "respiratory questionnaire, and living qulity was elevated. The patients inhaling salmeteroL/ fluticasone propionate showed better compliance than those inhaling tiotropium bromide, and got less acute episodes, while aggravated infection. Conclusion Both inhalation of salmeterol/ flutieasone propionate and inhalation of tiotropium bromide have good therapeutic effects on lung function and life quality of patients with COPD at stationary phases. The patients inhaling salmeterol/ fluticasone propionate show better compliance than those inhaling tiotropium bromide, but may develop more infection.
出处 《医药导报》 CAS 2009年第9期1149-1151,共3页 Herald of Medicine
关键词 噻托溴铵 沙美特罗替卡松 肺疾病 阻塞性 慢性 Tiotropium Salmeterol/fluticasone propionate Pulmonary disease, obstructive, chronic
  • 相关文献

参考文献8

  • 1ROMAIN A,PAUWELS A,SONIA B et al.Global strategy for the diagnosis,management,and prevention of chronic obstructive pulmonary disease[J].Am J Respir Crit Care Med,2001,163(5):1256-1276.
  • 2慢性阻塞性肺疾病诊治指南(2007年修订版)[J].中华结核和呼吸杂志,2007,30(1):8-17. 被引量:8233
  • 3郑劲平,康健,蔡柏蔷,周新,曹兆龙,白春学,钟南山.吸入噻托溴铵干粉与异丙托溴铵定量气雾剂治疗慢性阻塞性肺疾病的疗效与安全性比较[J].中华结核和呼吸杂志,2006,29(6):363-367. 被引量:158
  • 4陆再英,钟南山.内科学[M].7版.北京:人民卫生出版社,2008:717-718.
  • 5WIN T,PEARCE L,NATHAN J,et al.Use of the airway questionnaire 20 to detect changes in quality of life in asthmatic patients and its association with the St George's respiratory questionnaire and clinical parameters[J].Can Respir J,2008,15(3):133-140.
  • 6HANSEL T T,BARNES P J.Tiotropium bromide:a novel once-daily anticholinergic bronchodilator for the treatment of COPD[J].Drugs Today(Barc),2002,38(9):585-600.
  • 7LA VECCHIA C,FABBRI L M.Prevention of death in COPD[J].N Engl J Med,2007,356(12):2211-2212.
  • 8KEATING G M,MCCORMACK P L.Salmeterol/fluticasone propionate:a review of its use in the treatment of chronic obstructive pulmonary disease[J].Drugs,2007,67(16):383-405.

二级参考文献18

  • 1刘升明,王小平,王大礼,周玉民,吕嘉春,郑劲平,钟南山,冉丕鑫.广东部分地区慢性阻塞性肺疾病发病状况调查[J].中华医学杂志,2005,85(11):747-752. 被引量:150
  • 2有创-无创序贯机械通气多中心研究协作组.以肺部感染控制窗为切换点行有创与无创序贯机械通气治疗慢性阻塞性肺疾病所致严重呼吸衰竭的随机对照研究[J].中华结核和呼吸杂志,2006,29(1):14-18. 被引量:279
  • 3Barnes PJ,Stockley RA.COPD:current therapeutic interventions and future approaches.Eur Respir J,2005,25:1084-1106.
  • 4Disse B,Reichl R,Speck G,et al.Ba 679 BR,a novel long-acting anticholinergic bronchodilator.Life Sci,1993,52:537-544.
  • 5Takahashi T,Belvisi MG,Patel H,et al.Effect of Ba 679 BR,a novel long-acting anticholinergic agent,on cholinergic neurotransmission in guinea pig and human airways.Am J Respir Crit Care Med,1994,150(6 Pt 1):1640-1645.
  • 62003 Update:Workshop Report,Global Strategy for Diagnosis,Management,and Prevention of COPD.National Heart,Lung,and Blood Institute and World Health Organization,Global initiative for chronic obstructive lung disease (GOLD).Available from:http://www.goldeopd.org/
  • 7Casaburi R,Mahler DA,Jones PW,et al.A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease.Eur Respir J,2002,19:217-224.
  • 8Littner MR,Ilowite JS,Tashkin DP,et al.Long-acting bronchodilation with once-daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary disease.Am J Respir Crit Care Med,2000,161 (4 Pt 1):1136-1142.
  • 9Casaburi R,Briggs DD Jr,Donohue JF,et al.The spirometric efficacy of once-daily dosing with tiotropium in stable COPD:a 13-week multicenter trial.The US Tiotropium Study Group.Chest,2000,118:1294-1302.
  • 10O'Donnell DE,Fluge T,Gerken F,et al.Effects of tiotropium on lung hyperinflation,dyspnoea and exercise tolerance in COPD.Eur Respir J,2004,23:832-840.

共引文献8955

同被引文献48

  • 1慢性阻塞性肺疾病诊治指南(2007年修订版)[J].中华结核和呼吸杂志,2007,30(1):8-17. 被引量:8233
  • 2侯晓宁,李治.老年慢性阻塞性肺病患者应慎用噻托溴铵[J].药物流行病学杂志,2007,16(1):55-56. 被引量:2
  • 3陈灏珠.实用内科学[M].第12版.北京:人民卫生出版社,2002:1640.
  • 4Rabe KF, Hurd S, Aniueto A, et al. Global strategy for the diagnosis, management , and prevent ion of chronic obstructive pulmonary disease: GOLD executive summary [J] . Am J Respir Crit Care Med, 2007, 176 (6) :532-555.
  • 5Fabbri L, Pauwels RA, Hurd SS. Global strategy for the diagnosi; s, management, and prevent ion of chronic obstructive pulmonary disease: GOLD executive sum- mary updated 2003[J] . Copd, 2004, 1(1): 105-141.
  • 6Oostenbrink JB, van Molken R, van Noord JA, et al. One- year cost-effectiveness of tiotropium versus iprat- ropium to treat chronic obstructive pulmonary disease [J] . Eur Respir J, 2004, 23(2) :241-249.
  • 7Jones PW, Willits LR, Burge PS, et al. Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations[J] . Eur Respir J, 2003, 21(1): 68- 73.
  • 8Wnt , Pearce L , Nathan J, et al. Use of the airway questionnaire 20 to detect changes in quality of life in asthm atic patients and its association with the St George's respiratory questionnaire and clini- cal parameters [J]. Can Respir J, 2008, 15(3) : 133 -140.
  • 9BARNES P J.The cytokine network in asthma and chronic obstructive pulmonary disease[J].Clin Invest,2008,118(11):3546-3556.
  • 10CALVERLEY P M,ANDERSON J A,CELLI B,et al.On behalf of the TORCH investigators,salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease[J].N Engl J Med,2007,356:775-789.

二级引证文献49

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部